The Clinical Characteristics and Prognosis of Patients with Light-Chain Amyloidosis: A Retrospective Analysis.
10.19746/j.cnki.issn.1009-2137.2025.02.043
- Author:
Dan ZHAO
1
;
Zeng-Kai WANG
2
;
Ting-Ting CHEN
1
;
Bing-Jie YAO
1
Author Information
1. Department of Clinical Laboratory, The First Affiliated Hospital of Dalian Medical University, Dalian 116000, Liaoning Province, China.
2. Dalian Municipal Central Hospital, Dalian 116000, Liaoning Province, China.
- Publication Type:Journal Article
- Keywords:
light-chain amyloidosis;
clinical characteristics;
prognosis;
risk factors
- MeSH:
Humans;
Retrospective Studies;
Prognosis;
Middle Aged;
Male;
Female;
Aged;
Immunoglobulin Light-chain Amyloidosis/diagnosis*;
Adult;
Aged, 80 and over;
Kaplan-Meier Estimate
- From:
Journal of Experimental Hematology
2025;33(2):593-600
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To retrospectively analyze the clinical characteristics, prognosis and prognostic factors of patients with light-chain (AL) amyloidosis, so as to provide reference for the diagnosis and treatment of AL amyloidosis.
METHODS:Clinical data of 52 patients diagnosed with AL amyloidosis at two hospitals from January 2017 to November 2022 were collected. The clinical characteristics, differences in clinical indexes between the deceased group and the survival group were analyzed. Kaplan-Meier curves were used for overall survival (OS) analysis, and Cox regression models were used to analyze the factors affecting the prognosis.
RESULTS:The median age of the 52 patients at diagnosis was 61(41-81) years old, and 63.5% of the patients were male. Heart (69.2%) and kidney (67.3%) were the most involved organs, and 67.3% of the patients had two or more organs involved. Most patients (71.2%) received chemotherapy regimens containing bortezomib, including 5 patients (9.6%) who received treatment with daratumumab in combination with bortezomib. The proportion of male patients (81.0%), the proportion of patients with cardiac involvement (95.2%), and the proportion of patients with Mayo 2012 stage ≥III (95.2%), as well as the levels of hs-cTnI and NT-proBNP in the deceased group were significantly higher than those in the survival group ( P < 0.05). The median OS time of the enrolled patients was 33.4(2.6-60.2) months, with 1-year, 2-year, 3-year and 5-year OS rates of 83.7%, 79.3%, 58.9% and 32.7%, respectively. The Kaplan-Meier survival curve analysis revealed that patients with male gender (P =0.040), NT-proBNP ≥3 600 ng/L ( P < 0.001), Mayo 2012 stage ≥III ( P < 0.001), and cardiac involvement (P =0.008) had poor prognosis and shorter overall survival (OS) time. The multivariate regression analysis showed that Mayo 2012 stage ≥III was an independent risk factor for prognosis.
CONCLUSION:In recent years, the survival rate of patients with AL amyloidosis has improved significantly, but the 5-year survival rate is still relatively low. Cardiac biomarkers (NT-proBNP and hs-cTnI) and Mayo 2012 stage at diagnosis continue to provide important prognostic information. Bortezomib-based regimens were used as the primary treatment in most patients, and the addition of daratumumab is becoming increasingly common.
